NSPR - InspireMD, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

InspireMD, Inc.

4 Menorat Hamaor Street
Tel Aviv 6744832
972 3 6917691

IndustryMedical Devices
Full Time Employees55

Key Executives

NameTitlePayExercisedYear Born
Mr. Marvin L. SlosmanPres, CEO & Director696.81kN/A1964
Mr. Craig ShoreCFO, Chief Admin. Officer, Sec. & Treasurer625.24kN/A1961
Mr. Andrea TommasoliChief Operating Officer359.27kN/A1972
Mr. Shane Thomas GleasonGM of North America & VP of Global MarketingN/AN/A1975
Mr. Amir KohenVP of Fin. & International HRN/AN/AN/A
Dr. Sol J. Barer Ph.D.Special Advisor to the BoardN/AN/A1947
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Corporate Governance

InspireMD, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.